Department of Medicine and Public Health Sciences, University of Alberta, Edmonton, AB, Canada.
Nephrol Dial Transplant. 2012 Oct;27(10):3849-55. doi: 10.1093/ndt/gfs267. Epub 2012 Jul 2.
To investigate the relation of residence location, markers of good quality healthcare and adverse clinical outcomes in patients with diabetes and chronic kidney disease (CKD).
We identified 31 337 individuals with diabetes and estimated glomerular filtration rate (eGFR) 15-59 mL/min/1.73 m(2) from a population-based cohort (n= 1 278 375) of adults with serum creatinine measured at least once during 2005 or 2006 in Alberta, Canada. The study population was classified into categories based on travel distance by road from residence location to the closest nephrologist: (0-50, 50.1-100, 100.1-200 and >200 km).
At follow-up, compared with those living within 50 km, remote dwellers were less likely to visit a nephrologist, less likely to have hemoglobin A1c and urinary albumin measured within 1 year of the index eGFR, and less likely to receive an angiotensin converting enzyme inhibitor, angiotensin receptor blocker or statin (all P < 0.0001). In adjusted models, compared with those with CKD (Stage 3 or 4) living within 50 km, the adjusted likelihood of all-cause hospitalization was [1.4 (95% confidence interval, CI, 1.3-1.6)], [1.3 (95% CI, 1.1-1.6)] and [1.3 (95% CI, 1.2-1.5)]-fold higher for patients living 50.1-100, 100.1-200 and >200 km away from a nephrologist, respectively (P < 0.0001). The hazard ratio of all-cause mortality increased with increasing distance: [1.07 (95% CI, 0.9-1.2)], [1.1 (95% CI, 0.9-1.2)] and [1.2 (95% CI, 1.0-1.4)], respectively (P < 0.0001).
Compared with those living closer to a nephrologist, remote dwellers with diabetes and CKD were less likely to receive recommended quality care, and more likely to experience adverse health outcomes.
研究目的在于探究在患有糖尿病和慢性肾病(CKD)的患者中,居住地点、高质量医疗保健标志物与不良临床结局之间的关系。
我们从加拿大阿尔伯塔省一个基于人群的队列中(2005 或 2006 年至少有一次血清肌酐检测)确定了 31337 名糖尿病且估算肾小球滤过率(eGFR)为 15-59mL/min/1.73m²的成年人,根据居住地点到最近肾病医生的道路距离,将研究人群分为以下几类:(0-50、50.1-100、100.1-200 和 >200km)。
在随访期间,与居住在 50km 以内的患者相比,偏远地区的患者不太可能去看肾病医生,不太可能在指数 eGFR 后 1 年内测量血红蛋白 A1c 和尿白蛋白,也不太可能接受血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂或他汀类药物治疗(均 P < 0.0001)。在调整模型中,与居住在 50km 以内的 CKD(3 期或 4 期)患者相比,居住在距离肾病医生 50.1-100、100.1-200 和>200km 的患者发生全因住院的校正后可能性分别高出[1.4(95%置信区间,CI,1.3-1.6)]、[1.3(95%CI,1.1-1.6)]和[1.3(95%CI,1.2-1.5)]倍(均 P < 0.0001)。全因死亡率的风险比随距离增加而增加:[1.07(95%CI,0.9-1.2)]、[1.1(95%CI,0.9-1.2)]和[1.2(95%CI,1.0-1.4)](均 P < 0.0001)。
与距离肾病医生更近的患者相比,患有糖尿病和 CKD 的偏远地区居民获得推荐质量护理的可能性较低,且更有可能出现不良健康结局。